Fig. 1.

AT-SPMs or aspirin inhibits primary tumor growth. (A) AT-RvD1, AT-RvD3, or AT-LXA₄ (0.6 μg/kg/d) with primary LLC tumor growth. Treatment was initiated on the day of tumor cell injection throughout. Values are represented as mean ± SEM; n = 5–10 mice/group. The two-tailed Student t test was used for final tumor measurements. *P < 0.05 vs. control. (B) Aspirin (30 mg/kg/d used throughout) with orthotopic LLC tumor growth. n = 4–5 mice/group. *P < 0.05 vs. control. Lungs were resected and weighed, and visible metastatic nodules were counted at 19 d after LLC injection. *P < 0.05 vs. control. (C) LC-MS/MS fragmentation spectra of AT-RvD1, AT-RvD3, and AT-LXA₄ in LLC tumor tissue from mice systemically treated with aspirin (30 mg/kg/d) for 9 d.